Skip to main content

Trial Milestone MAC22 has over 10,000 patients Accrued!

Trial Milestone MAC22 has over 10,000 patients Accrued!

CCTG MAC22 TMIST - Tomosynthesis Mammographic Imaging Screening Trial (NCT03233191) has accrued an impressive 10,027 Canadians to the study. Congratulations to the trial team and all of the participating centers across Canada.

This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening tmist dr Seelyand may help reduce the need for additional imaging or treatment.

Eligibility:Patients must be women between the age 45 and 75 at the time of study entry. Women of childbearing potential must not be known to be pregnant or lactating Patients must be scheduled for, or have intent to schedule, a screening mammogram Patients must be able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol. Written informed consent No symptoms or signs of benign or malignant breast disease No screening mammogram within the last 11 months prior to date of randomization No previous personal history of breast cancer including ductal carcinoma in situ No breast enhancements

Objectives: To compare the proportions of participants in the Tomosynthesis (TM) and Digital Mammography (DM) study arms experiencing the occurrence of an advanced breast cancer at any time during a period of 4.5 years from randomization, including the period of active screening and a period of clinical follow-up after the last screen

For more information please visit the CCTG MAC22 Trial Page

Canadian Participating Centres

British Columbia

  • BCCA-Vancouver Cancer Centre - Principal Investigator: Paula B. Gordon

Ontario

  • Saint Joseph's Health Centre -Principal Investigator: Anat Kornecki
  • Ottawa Hospital and Cancer Center- Principal Investigator: Jean M. Seely
  • Odette Cancer Centre- Sunnybrook Health Sciences Centre - Principal Investigator: Roberta A. Jong
  • Mount Sinai Hospital R - Principal Investigator: Vivianne A. Freitas

Quebec

  • Hopital Du Sacre-Coeur de Montreal - Principal Investigator: Caroline Samson
  • CHU de Quebec-Hopital du Saint-Sacrement (HSS) - Principal Investigator: Christine Desbiens